Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1991 Feb;41(2):193-201.
doi: 10.2165/00003495-199141020-00005.

Osteoarthritis 1991. Current drug treatment regimens

Affiliations
Review

Osteoarthritis 1991. Current drug treatment regimens

A al Arfag et al. Drugs. 1991 Feb.

Erratum in

  • Drugs 1991 Apr;41(4):532

Abstract

Osteoarthritis, the most common rheumatic disease, presents the clinician with a major therapeutic and management task. The chronic and progressive course of the disease is punctuated by pain, declining function and escalating disability. This article attempts to deal with the pharmacological therapeutic options available to use in the management of osteoarthritis. Other non-pharmacological therapeutic modalities are also briefly discussed, including patient education, joint protection, physiotherapy, occupational therapy and surgery. Drug therapy as discussed focuses on the control of pain and inflammation. For this intermittently painful condition analgesic drugs assume a very important role. Non-steroidal anti-inflammatory drugs (NSAIDs) have combined analgesic and anti-inflammatory properties which are particularly useful in many patients who manifest inflammation in addition to pain. While systemic steroids have no role in the treatment of osteoarthritis, intra-articular steroid injections may be of benefit. In trying to slow the degenerative process chondroprotective agents such as glycosaminoglycan may also assume increasing importance in the future. Choosing one drug over another must be done after consideration of many factors including the therapeutic and toxicity profile of the drugs involved, their pharmacology and dose regimen, the patient profile, cost and the desired effect.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Arthritis Rheum. 1970 May-Jun;13(3):236-43 - PubMed
    1. N Engl J Med. 1984 Feb 2;310(5):279-83 - PubMed
    1. J Rheumatol. 1987 May;14 Spec No:7-10 - PubMed
    1. Semin Arthritis Rheum. 1987 Nov;17(2 Suppl 1):35-53 - PubMed
    1. J Bone Joint Surg Am. 1973 Apr;55(3):545-57 - PubMed

MeSH terms

LinkOut - more resources